Serpin B-1 (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human Serpin B-1 (SERPINB1; UniProt P30740), expressed in HEK293 cells. Suitable for neutrophil serine protease inhibition assays, caspase suppression studies, inhibitor screening, and antibody validation.
Expression system
HEK293
Cat. #
REC-SerpinB1

In stock

SKU
REC-SerpinB1
$498.00

Target Overview

Serpin B-1 (SERPINB1; UniProt P30740) is a 379-amino-acid intracellular serine protease inhibitor belonging to the clade B (ovalbumin) serpin family. Unlike most secreted serpins, Serpin B-1 functions primarily in the cytoplasm, where it guards against proteolytic damage during neutrophil activation, stress, and infection. It inhibits a defined panel of neutrophil serine proteases — including elastase, cathepsin G, proteinase-3, chymase, and kallikrein-3 — as well as the cytotoxic lymphocyte protease granzyme H (GZMH) and, during inflammatory signalling, the caspase-recruitment domain (CARD)-dependent activation of inflammatory caspases CASP1, CASP4, and CASP5. Under certain conditions, the protein is also found in the extracellular space, where it has been reported to influence beta-cell proliferation through its protease inhibitory activity. This recombinant is expressed in HEK293 cells, providing a mammalian post-translational processing environment appropriate for folding-sensitive inhibitory studies. The full-length sequence (residues 1–379) is produced, preserving the reactive-centre loop (RCL) responsible for protease engagement. Researchers use this reagent primarily in three experimental contexts: (1) direct enzyme inhibition assays measuring the rate of elastase, cathepsin G, or GZMH inhibition under defined stoichiometric conditions; (2) inhibitor or small-molecule screening campaigns where Serpin B-1 serves as a reference standard or competitive control; and (3) antibody validation, where the recombinant provides a defined positive-control antigen for Western blot and ELISA confirmation. Researchers requiring a matched antibody reagent can pair this recombinant with Triple Point Biologics' corresponding anti-Serpin B-1 antibody (SKU: RP-SerpinB1), validated for Western blot against human samples.

Background

Serpin B-1 (SERPINB1) occupies a well-defined position at the intersection of innate immunity regulation, intracellular proteostasis, and inflammation control. It was initially characterised as a leukocyte elastase inhibitor (LEI) and monocyte/neutrophil elastase inhibitor (M/NEI), and its inhibitory breadth has since been extended to include cathepsin G, proteinase-3, chymase, chymotrypsin, kallikrein-3, and granzyme H — a profile that situates it as a broad-spectrum guardian against cytoplasmic granule proteases released during neutrophil degranulation or cell lysis. A mechanistically distinct function was characterised for its role in inflammasome regulation: Serpin B-1 suppresses the CARD-domain oligomerisation required for enzymatic activation of caspases CASP1, CASP4, and CASP5, positioning it as a physiological brake on inflammatory caspase cascades independently of classical RCL-mediated inhibition. This dual mechanism — direct active-site inhibition of serine proteases and allosteric suppression of caspase activation — makes Serpin B-1 an informative tool for dissecting compartment-specific proteolytic signalling in cell-based models. In published research, SERPINB1 has been investigated as a research target in pulmonary biology: Hao et al. (2026) demonstrated that SerpinB1 modulates macrophage-to-pulmonary arterial smooth muscle cell (PASMC) crosstalk and studied its role in protecting against hypoxia-induced pulmonary hypertension in preclinical models, providing mechanistic context for its anti-inflammatory function in the vascular compartment (PMID: 41498134). Separately, SERPINB1 has been identified in proteomic discovery studies of saliva and dental tissue, where its differential abundance across disease states has been catalogued using mass spectrometry-based workflows. Its reported interaction with porcine deltacoronavirus accessory protein NS7a has also attracted attention in viral replication research. Beyond these contexts, extracellular Serpin B-1 has been studied in metabolic research for its reported promotion of pancreatic beta-cell proliferation via protease inhibitory activity — a function relevant to researchers modelling beta-cell biology in vitro. For laboratories running inhibitor-counterscreen assays, Serpin B-1 is a standard reference serpin for confirming assay specificity, given its well-characterised second-order association rate constants with elastase and cathepsin G. Triple Point Biologics has produced proteinase and inhibitor antibody reagents since 1994; this recombinant was developed to complement that antibody portfolio and support quantitative inhibition studies.

Applications

  • Neutrophil elastase inhibition activity assay (stoichiometric titration or progress-curve format)
  • Cathepsin G and proteinase-3 inhibition kinetics (second-order rate constant determination)
  • Granzyme H (GZMH) direct proteolytic activity inhibition assay
  • Inflammatory caspase (CASP1/CASP4/CASP5) suppression assay in cell-free reconstituted systems
  • Inhibitor counterscreen: recombinant Serpin B-1 as competitive reference standard in serine protease small-molecule screens
  • Antibody validation positive control for Western blot and ELISA (pair with matched Triple Point Biologics anti-Serpin B-1, SKU: RP-SerpinB1)
  • Mass spectrometry-based substrate identification: recombinant protein as bait in pull-down or co-IP workflows
  • ELISA standard curve preparation for quantification of Serpin B-1 in conditioned media or cell lysates

References

  1. Hao J et al. Targeting Macrophage Crosstalk to PASMC by Blunting Inflammatory Phenotype Via SerpinB1 Protects Against Hypoxia-Induced Pulmonary Hypertension. Hypertension. 2026. doi:10.1161/HYPERTENSIONAHA.125.25832. PMID: 41498134.
  2. Yan J et al. SERPINB1 promotes porcine deltacoronavirus replication by targeting the viral accessory protein NS7a. Vet Microbiol. 2026. doi:10.1016/j.vetmic.2025.110869. PMID: 41477939.
  3. Rattanapornsompong K et al. Saliva Proteomics Shows Immune Activation and Metabolic Shifts in Female Jalili Syndrome Patients. Oral Dis. 2026. doi:10.1111/odi.70273. PMID: 41876952.
  4. Vidal CMP et al. Stage-Specific Proteomic Profiles in Dental Caries. J Dent Res. 2026. doi:10.1177/00220345251392212. PMID: 41305856.
  5. Liu L et al. SLC22A4 as a candidate regulator linking immunity and ferroptosis in septic shock. Mol Immunol. 2026. doi:10.1016/j.molimm.2026.06.007. PMID: 42275906.

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Secreted; blood plasma

Frequently Asked Questions

What molecular weight band should I expect for recombinant Serpin B-1 on SDS-PAGE or Western blot?

Serpin B-1 (SERPINB1, UniProt P30740) is a 379-amino-acid protein with a calculated molecular weight of approximately 42 kDa. On reducing SDS-PAGE, our HEK293-expressed recombinant typically runs at 44–46 kDa — the slight upward shift relative to the calculated mass is common for serpins and reflects the compact, globular fold rather than any glycosylation event (SERPINB1 is not a glycoprotein). Purity is >95% by SDS-PAGE. A clean single band at this position is the expected result under standard reducing conditions.

Which proteases does recombinant Serpin B-1 inhibit and what is its mechanism of action?

Serpin B-1 functions as a suicide-substrate inhibitor — it forms a covalent, SDS-stable complex with its target protease via a reactive-centre loop (RCL) mechanism. Validated targets include neutrophil elastase, cathepsin G, proteinase-3, chymase, and kallikrein-3, as well as the lymphocyte granule protease granzyme H (GZMH). It also suppresses CARD-dependent activation of inflammatory caspases CASP1, CASP4, and CASP5. If your experiment involves neutrophil serine protease signalling or inflammasome regulation, confirm that your chosen target is on this list before designing inhibition assays.

What substrate and assay conditions should I use to measure Serpin B-1 inhibitory activity against neutrophil elastase?

A standard approach is a fluorescence-based progress-curve assay using the synthetic substrate MeOSuc-AAPV-AMC (50–200 µM) with human neutrophil elastase (HNE) as the target enzyme in 50 mM HEPES pH 7.4, 150 mM NaCl, 0.01% Tween-20 at 37°C. Pre-incubate Serpin B-1 with HNE for 5–15 minutes before adding substrate, since serpin inhibition is time-dependent. Monitor AMC release at Ex/Em 360/460 nm. Association rate constants (ka) for SERPINB1–HNE are in the range of 10⁶–10⁷ M⁻¹s⁻¹, so even nanomolar concentrations of inhibitor produce measurable suppression within minutes.

What starting concentration of recombinant Serpin B-1 should I use for a neutrophil elastase inhibition assay?

For a standard stoichiometry-of-inhibition (SI) or progress-curve experiment, start with 50–500 nM Serpin B-1 and titrate against a fixed HNE concentration (e.g., 10–50 nM enzyme). Because serpins form 1:1 covalent complexes with a stoichiometric inhibition ratio typically between 1 and 2, you can estimate the active inhibitor fraction from the molar ratio at which full inhibition is achieved. Avoid using molar excess >10-fold over enzyme in initial screens, as non-specific background can obscure the SI calculation. Our recombinant is provided at a defined concentration stated on the vial CoA.

Does the storage buffer for recombinant Serpin B-1 interfere with serine protease activity assays?

The storage buffer — 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol — is compatible with most fluorogenic serine protease assays at standard dilutions of 1:10 or greater into assay buffer. Glycerol at the working concentration (≤1% after dilution) has negligible effect on HNE or cathepsin G activity. Tris can interfere with some colorimetric substrates, so if you are using a pNA-coupled substrate, dilute into HEPES-based assay buffer instead. The buffer contains no EDTA, DTT, or protease inhibitor cocktail components that would confound serpin inhibition readouts.

Can I use recombinant Serpin B-1 as a positive control for Western blot with the matched RP-SerpinB1 antibody?

Yes — this is a validated pairing. The matched rabbit polyclonal antibody RP-SerpinB1 (/anti-serpin-b1-rabbit-polyclonal-antibody) was raised in the same laboratory that produced this recombinant, ensuring antigen–antibody compatibility. Load 20–50 ng of recombinant protein per lane alongside your cell lysate lanes. Expect a single band at 44–46 kDa under reducing conditions. This setup provides a reliable size and signal reference when validating RP-SerpinB1 on new cell or tissue lysates, and is particularly useful when working with samples where endogenous SERPINB1 expression is low or variable (e.g., non-neutrophil lines).

How much recombinant Serpin B-1 should I load as a Western blot positive control to avoid signal saturation?

In our hands, 20–50 ng per lane gives a clean, quantifiable band with RP-SerpinB1 at antibody dilutions of 1:1,000–1:5,000 using standard HRP-conjugated secondaries and chemiluminescent detection. If you are using fluorescent secondary detection, 50–100 ng may be preferable to remain in the linear dynamic range of your imager. Run a brief titration (10, 25, 50, 100 ng) on the first use with a new lot of RP-SerpinB1, as secondary antibody and detection system variables affect optimal loading more than the primary antibody in most WB workflows.

How should I handle, dilute, and store recombinant Serpin B-1 to maintain activity over time?

Serpin B-1 is supplied in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol in single-use aliquots and should be stored at -20°C. Avoid repeated freeze-thaw cycles, as each cycle can reduce the fraction of correctly folded, inhibition-competent serpin. Upon first thaw, briefly centrifuge the vial (1,000 × g, 30 s) to collect any condensate, then keep on ice during use. For dilutions below ~100 nM, add BSA (0.1 mg/mL) to the working buffer to prevent adsorptive losses to tube walls. Working aliquots stored at 4°C are stable for up to 48 hours; re-freeze unused material only if aliquot design permits single use.

Validation imagery coming soon

Western blot validation figures for REC-SerpinB1 will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →